Page 1574 - Williams Hematology ( PDFDrive )

1548 Part XI: Malignant Lymphoid Diseases Chapter 92: Chronic Lymphocytic Leukemia 1549

308. Stephens DM, Ruppert AS, Maddocks K, et al: Cyclophosphamide, alvocidib (flavopiridol), 337. Chiappa S, Bonadonna G, Uslenghi C, et al: The role of endolymphatic radiotherapy in
and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high- the treatment of chronic lymphatic leukaemia. Br J Cancer 20:480–484, 1966.
risk chronic lymphocytic leukemia. Leuk Res 37:1195–1199, 2013. 338. Cooper IA, Ding JC, Adams PB, et al: Intensive leukapheresis in the management of
309. Lin TS, Ruppert AS, Johnson AJ, et al: Phase II study of flavopiridol in relapsed chronic cytopenias in patients with chronic lymphocytic leukaemia (CLL) and lymphocytic
lymphocytic leukemia demonstrating high response rates in genetically high-risk lymphoma. Am J Hematol 6:387–398, 1979.
disease. J Clin Oncol 27:6012–6018, 2009. 339. Cukierman T, Gatt ME, Libster D, et al: Chronic lymphocytic leukemia presenting
310. Fabre C, Gobbi M, Ezzili C, et al: Clinical study of the novel cyclin-dependent kinase with extreme hyperleukocytosis and thrombosis of the common femoral vein. Leuk
inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lym- Lymphoma 43:1865–1868, 2002.
phocytic leukemia patients. Cancer Chemother Pharmacol 74:1057–1064, 2014. 340. Ali R, Ozkalemkas F, Ozkocaman V, et al: Successful labor in the course of chronic
311. Blachly JS, Byrd JC: Emerging drug profile: Cyclin-dependent kinase inhibitors. Leuk lymphocytic leukemia (CLL) and management of CLL during pregnancy with leuka-
Lymphoma 54:2133–2143, 2013. pheresis. Ann Hematol 83:61–63, 2004.
312. Magni M, Di Nicola M, Patti C, et al: Results of a randomized trial comparing high-dose 341. Cheson BD, Byrd JC, Rai KR, et al: Novel targeted agents and the need to refine clinical
chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis. Bone Marrow Transplant end points in chronic lymphocytic leukemia. J Clin Oncol 30:2820–2822, 2012.
49:485–491, 2014. 342. Rawstron AC, Villamor N, Ritgen M, et al: International standardized approach
313. Sutton L, Chevret S, Tournilhac O, et al: Autologous stem cell transplantation as a first- for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.
line treatment strategy for chronic lymphocytic leukemia: A multicenter, randomized, Leukemia 21:956–964, 2007.
controlled trial from the SFGM-TC and GFLLC. Blood 117:6109–6119, 2011. 343. Raponi S, Della Starza I, De Propris MS, et al: Minimal residual disease monitoring in
314. Tam CS, Khouri I: The role of stem cell transplantation in the management of chronic chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and
lymphocytic leukaemia. Hematol Oncol 27:53–60, 2009. ASO IgH RQ-PCR. Br J Haematol 166:360–368, 2014.
315. Peres E, Braun T, Krijanovski O, et al: Reduced intensity versus full myeloablative stem 344. Bottcher S, Ritgen M, Pott C, et al: Comparative analysis of minimal residual disease
cell transplant for advanced CLL. Bone Marrow Transplant 44:579–583, 2009. detection using four-color flow cytometry, consensus IgH-PCR, and quantitative
316. Doney KC, Chauncey T, Appelbaum FR, et al: Allogeneic related donor hematopoietic IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia
stem cell transplantation for treatment of chronic lymphocytic leukemia. Bone Marrow 18:1637–1645, 2004.
Transplant 29:817–823, 2002. 345. Rawstron AC, Bottcher S, Letestu R, et al: Improving efficiency and sensitivity: European
317. Dreger P, Schetelig J, Andersen N, et al: Managing high-risk CLL during transition to Research Initiative in CLL (ERIC) update on the international harmonised approach for
a new treatment era: Stem cell transplantation or novel agents? Blood 124:3841–3849, flow cytometric residual disease monitoring in CLL. Leukemia 27:142–149, 2013.
2014. 346. Provan D, Bartlett-Pandite L, Zwicky C, et al: Eradication of polymerase chain reaction-
318. Sorror ML, Storer BE, Sandmaier BM, et al: Five-year follow-up of patients with detectable chronic lymphocytic leukemia cells is associated with improved outcome
advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell after bone marrow transplantation. Blood 88:2228–2235, 1996.
transplantation after nonmyeloablative conditioning. J Clin Oncol 26:4912–4920, 2008. 347. Moreton P, Kennedy B, Lucas G, et al: Eradication of minimal residual disease in B-cell
319. Dreger P, Dohner H, Ritgen M, et al: Allogeneic stem cell transplantation provides chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged
durable disease control in poor-risk chronic lymphocytic leukemia: Long-term clinical survival. J Clin Oncol 23:2971–2979, 2005.
and MRD results of the German CLL Study Group CLL3X trial. Blood 116:2438–2447, 348. Royle JA, Baade PD, Joske D, et al: Second cancer incidence and cancer mortality
2010. among chronic lymphocytic leukaemia patients: A population-based study. Br J Cancer
320. Khouri IF, Bassett R, Poindexter N, et al: Nonmyeloablative allogeneic stem cell trans- 105:1076–1081, 2011.
plantation in relapsed/refractory chronic lymphocytic leukemia: Long-term follow-up, 349. Benjamini O, Jain P, Trinh L, et al: Second cancers in patients with Chronic Lympho-
prognostic factors, and effect of human leukocyte histocompatibility antigen subtype cytic Leukemia who received frontline FCR therapy—Distribution and clinical out-
on outcome. Cancer 117:4679–4688, 2011. comes. Leuk Lymphoma 1–28, 2014.
321. Brown JR, Kim HT, Armand P, et al: Long-term follow-up of reduced-intensity alloge- 350. Travis LB, Curtis RE, Hankey BF, et al: Second cancers in patients with chronic lympho-
neic stem cell transplantation for chronic lymphocytic leukemia: Prognostic model to cytic leukemia. J Natl Cancer Inst 84:1422–1427, 1992.
predict outcome. Leukemia 27:362–369, 2013. 351. Davis JW, Weiss NS, Armstrong BK: Second cancers in patients with chronic lympho-
322. Dreger P, Montserrat E; European Society for Blood and Marrow Transplantation cytic leukemia. J Natl Cancer Inst 78:91–94, 1987.
(EBMT); European Research Initiative on CLL (ERIC): Where does allogeneic stem 352. Brewer JD, Shanafelt TD, Otley CC, et al: Chronic lymphocytic leukemia is associated
cell transplantation fit in the treatment of chronic lymphocytic leukemia? Curr Hematol with decreased survival of patients with malignant melanoma and Merkel cell carci-
Malig Rep 10:59–64, 2015. noma in a SEER population-based study. J Clin Oncol 30:843–849, 2012.
323. Dreger P, Brand R, Milligan D, et al: Reduced-intensity conditioning lowers treat- 353. Solomon BM, Rabe KG, Slager SL, et al: Overall and cancer-specific survival of patients
ment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leu-
leukemia: A population-matched analysis. Leukemia 19:1029–1033, 2005. kemia: A SEER population-based study. J Clin Oncol 31:930–937, 2013.
324. Jaglowski SM, Ruppert AS, Heerema NA, et al: Complex karyotype predicts for inferior 354. Quaglino D, Paterlini P, De Pasquale A, et al: Association of chronic lymphocytic
outcomes following reduced-intensity conditioning allogeneic transplant for chronic leukaemia and multiple myeloma: Report of a case and review of the literature.
lymphocytic leukaemia. Br J Haematol 159:82–87, 2012. Haematologica 67:576–588, 1982.
325. Gratwohl A, Brand R, Niederwieser D, et al: Introduction of a quality management sys- 355. Pedersen-Bjergaard J, Petersen HD, Thomsen M, et al: Chronic lymphocytic leukaemia
tem and outcome after hematopoietic stem-cell transplantation. J Clin Oncol 29:1980– with subsequent development of multiple myeloma. Evidence of two B-lymphocyte
1986, 2011. clones and of myeloma-induced suppression of secretion of an M-component and of
326. Giebel S, Labopin M, Mohty M, et al: The impact of center experience on results of normal immunoglobulins. Scand J Haematol 21:256–264, 1978.
reduced intensity: Allogeneic hematopoietic SCT for AML. An analysis from the Acute 356. Jeha MT, Hamblin TJ, Smith JL: Coincident chronic lymphocytic leukemia and osteo-
Leukemia Working Party of the EBMT. Bone Marrow Transplant 48:238–242, 2013. sclerotic multiple myeloma. Blood 57:617–619, 1981.
327. Shanafelt TD, Kay NE, Rabe KG, et al: Hematologist/oncologist disease-specific exper- 357. Maeshima AM, Taniguchi H, Nomoto J, et al: Secondary CD5+ diffuse large B-cell
tise and survival: Lessons from chronic lymphocytic leukemia (CLL)/small lympho- lymphoma not associated with transformation of chronic lymphocytic leukemia/small
cytic lymphoma (SLL). Cancer 118:1827–1837, 2012. lymphocytic lymphoma (Richter syndrome). Am J Clin Pathol 131:339–346, 2009.
328. Hodgson K, Ferrer G, Pereira A, et al: Autoimmune cytopenia in chronic lymphocytic 358. Tsiodras S, Samonis G, Keating MJ, et al: Infection and immunity in chronic lympho-
leukaemia: Diagnosis and treatment. Br J Haematol 154:14–22, 2011. cytic leukemia. Mayo Clin Proc 75:1039–1054, 2000.
329. Coad JE, Matutes E, Catovsky D: Splenectomy in lymphoproliferative disorders: 359. Hensel M, Kornacker M, Yammeni S, et al: Disease activity and pretreatment, rather
A report on 70 cases and review of the literature. Leuk Lymphoma 10:245–264, 1993. than hypogammaglobulinaemia, are major risk factors for infectious complications in
330. Seymour JF, Cusack JD, Lerner SA, et al: Case/control study of the role of splenectomy patients with chronic lymphocytic leukaemia. Br J Haematol 122:600–606, 2003.
in chronic lymphocytic leukemia. J Clin Oncol 15:52–60, 1997. 360. Morrison VA: Infectious complications of chronic lymphocytic leukaemia: Patho-
331. Dearden C: Disease-specific complications of chronic lymphocytic leukemia. Hematology Am genesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol
Soc Hematol Educ Program 450–456, 2008. 23:145–153, 2010.
332. Byhardt RW, Brace KC, Wiernik PH: The role of splenic irradiation in chronic lympho- 361. Morra E, Nosari A, Montillo M: Infectious complications in chronic lymphocytic leu-
cytic leukemia. Cancer 35:1621–1625, 1975. kaemia. Hematol Cell Ther 41:145–151, 1999.
333. Aabo K, Walbom-Jorgensen S: Spleen irradiation in chronic lymphocytic leukemia 362. Wierda WG: Immunologic monitoring in chronic lymphocytic leukemia. Curr Oncol
(CLL): Palliation in patients unfit for splenectomy. Am J Hematol 19:177–180, 1985. Rep 5:419–425, 2003.
334. van Mook WN, Fickers MM, Verschueren TA: Clinical and immunological evaluation 363. Raanani P, Gafter-Gvili A, Paul M, et al: Immunoglobulin prophylaxis in chronic lym-
of primary splenic irradiation in chronic lymphocytic leukemia: A study of 24 cases. phocytic leukemia and multiple myeloma: Systematic review and meta-analysis. Leuk
Ann Hematol 80:216–223, 2001. Lymphoma 50:764–772, 2009.
335. Chanana AD, Cronkite EP, Rai KR: The role of extracorporeal irradiation of blood in 364. Boughton BJ, Jackson N, Lim S, et al: Randomized trial of intravenous immunoglobulin
treatment of leukemia. Int J Radiat Oncol Biol Phys 1:539–548, 1976. prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogam-
336. Wieselthier JS, Rothstein TL, Yu TL, et al: Inefficacy of extracorporeal photochemo- maglobulinaemia. Clin Lab Haematol 17:75–80, 1995.
therapy in the treatment of B-cell chronic lymphocytic leukemia: Preliminary results. 365. Gamm H, Huber C, Chapel H, et al: Intravenous immune globulin in chronic lympho-
Am J Hematol 41:123–127, 1992. cytic leukaemia. Clin Exp Immunol 97 Suppl 1:17–20, 1994.

Kaushansky_chapter 92_p1527-1552.indd 1549 9/18/15 10:49 AM